Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients

References

• Kivity S, Kopel E, Maor E, et al. Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol. 2013;111(8):1146–1151.
   PubMed Web of Science ®Google Scholar
• Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120(5):442–447.
   PubMed Web of Science ®Google Scholar
• Feig DI. Hyperuricemia and hypertension. Adv Chronic Kidney Dis. 2012;19(6):377–385.
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–2410.
   PubMed Web of Science ®Google Scholar
• Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Int Med. 2004;164(14):1546–1551.
   PubMedGoogle Scholar
• Maloberti A, Giannattasio C, Bombelli M, et al.; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) project. High Blood Press Cardiovasc Prev. 2020;27(2):121–128.
   PubMed Web of Science ®Google Scholar
• Yang TY, Fang CY, Chen JS, et al. Association of serum uric acid with cardiovascular disease in taiwanese patients with primary hypertension. Acta Cardiol Sin. 2015;31(1):42–51.
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894–900.
   PubMed Web of Science ®Google Scholar
• Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol: CJASN. 2011;6(10):2470–2477.
   PubMed Web of Science ®Google Scholar
• Sugano N, Maruyama Y, Kidoguchi S, et al. Effect of hyperuricemia and treatment for hyperuricemia in Japanese hemodialysis patients: A cohort study. PLoS One. 2019;14(6):e0217859.
   PubMed Web of Science ®Google Scholar
• Kim CS, Jin DC, Yun YC, et al. Relationship between serum uric acid and mortality among hemodialysis patients: Retrospective analysis of Korean end-stage renal disease registry data. Kidney Res Clin Pract. 2017;36(4):368–376.
   PubMed Web of Science ®Google Scholar
• Petreski T, Bevc S, Ekart R, et al. Hyperuricemia and long-term survival in patients with chronic kidney disease undergoing hemodialysis. CN. 2017;88(S1):69–72.
   Google Scholar
• Petreski T, Ekart R, Hojs R, et al. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis. Int Urol Nephrol. 2019;51(6):1013–1018.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793–808.
   PubMed Web of Science ®Google Scholar
• Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleveland Clinic J Med. 2006;73(12):1059–1064.
   PubMed Web of Science ®Google Scholar
• Pagonas N, Kor S, Seibert FS, et al. Effects of treatment of asymptomatic hyperuricemia on graft survival and mortality in kidney transplant recipients. Ann Transplant. 2016;21:350–359.
   PubMed Web of Science ®Google Scholar
• Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985;121(1):11–18.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78(2):147–153.
   PubMed Web of Science ®Google Scholar
• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–932.
   PubMed Web of Science ®Google Scholar
• Gunawardhana L, McLean L, Punzi HA, et al. Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study. JAHA. 2017;6(11):e006683.
   Google Scholar
• Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619–2624.
   PubMed Web of Science ®Google Scholar
• Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005;26(15):1544–1550.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Nitta K. Pathogenesis and management of vascular calcification in patients with end-stage renal disease. Contributions Nephrol. 2018;196:71–77.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. CJASN. 2010;5(8):1388–1393.
   PubMed Web of Science ®Google Scholar
• Lee JW, Lee KH. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol. 2019;51(3):467–473.
   PubMed Web of Science ®Google Scholar
• Simon-Santamaria J, Rinaldo CH, Kardas P, et al. Efficient uptake of blood-borne BK and JC polyomavirus-like particles in endothelial cells of liver sinusoids and renal vasa recta. PloS One. 2014;9(11):e111762.
   PubMed Web of Science ®Google Scholar
• https://aktn.org.au/ckd-fix/. https://aktn.org.au/ckd-fix/. Accessed.
   Google Scholar
• Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018;40(1):289–297.
   PubMed Web of Science ®Google Scholar
• Chewcharat A, Chen Y, Thongprayoon C, et al. Febuxostat as a renoprotective agent for treatment of hyperuricemia: a meta-analysis of randomized controlled trials. Intern Med J. 2020. DOI: https://doi.org/10.1111/imj.14814
   Google Scholar
• Jankowska M, Cobo G, Lindholm B, et al. Inflammation and Protein-Energy Wasting in the Uremic Milieu. Contributions Nephrol. 2017;191:58–71.
   PubMed Web of Science ®Google Scholar